International nonproprietary name: difference between revisions
Diff·revision 5 → 6·09:52, 29 Nov 2024
Difference between revision 5 and revision 6 of International nonproprietary name. 3 lines changed; the page grew by 178 bytes.
| Revision 5 — 14:11, 18 Nov 2024 SeeAlsoSelma (talk) attribute the mechanism claim to the review rather than stating it flatly 2,063 bytes +230 | Revision 6 — 09:52, 29 Nov 2024 CagriCass (talk) space between number and unit per PP:MOS 2,241 bytes +178 | ||
|---|---|---|---|
| 25 | The distinction between ''-glutide'' and ''-dutide'' encodes the difference between a GLP-1 analogue and a multi-receptor glucagon-family agonist, which is a real pharmacological distinction rather than a naming convenience. See [[Dual incretin agonist]].{{r|who_inn}} | 25 | The distinction between ''-glutide'' and ''-dutide'' encodes the difference between a GLP-1 analogue and a multi-receptor glucagon-family agonist, which is a real pharmacological distinction rather than a naming convenience. See [[Dual incretin agonist]].{{r|who_inn}} |
| 26 | 26 | ||
| + | 27 | Stems are extended and refined as classes proliferate, so a newly assigned name may use a stem that did not exist a decade earlier.{{r|who_inn}} | |
| + | 28 | ||
| 27 | == References == | 29 | == References == |
| 28 | {{reflist}} | 30 | {{reflist}} |
| ⋮ | ⋮ | ||
| 32 | [[Category:Drug nomenclature]] | 34 | [[Category:Drug nomenclature]] |
| 33 | [[Category:Compounds and pharmacology]] | 35 | [[Category:Compounds and pharmacology]] |
| + | 36 | [[Category:Reference material]] | |
| 34 | 37 |